The efficacy, safety, and tolerability of an estrogen-free oral contraceptive drospirenone 4 mg (24/4-day regimen) in obese users

Authors:

Abstract
No abstract available
Funding Information
  • Eastern Virginia Medical School
  • GlaxoSmithKline España (Medicines360)
  • Merck

This publication has 23 references indexed in Scilit: